上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (11): 1532-.doi: 10.3969/j.issn.1674-8115.2011.11.006

• 专题报道（双相障碍） • 上一篇    下一篇

双相障碍Ⅰ型患者血浆脑源性神经营养因子水平的变化

汪作为1,2, 李则挚1, 林治光1, 吴志国1, 苑成梅1, 洪 武1, 李春波1, 方贻儒1   

  1. 1.上海交通大学 医学院附属精神卫生中心, 上海 200030； 2.上海市虹口区精神卫生中心, 上海 200083
  • 出版日期:2011-11-28 发布日期:2011-11-29
  • 通讯作者: 方贻儒, 电子信箱: yirufang@yahoo.com.cn。
  • 作者简介:汪作为（1978—）, 男, 主治医师, 博士生；电子信箱: wzwhk@163.com。
  • 基金资助:

    国家自然科学基金（30971047）；国家高技术研究发展计划（“八六三”计划）(2006AA02Z430)；上海交通大学医学院“重点学科建设”基金（沪交医科[2008]-6）；上海交通大学医学院优秀博士学位论文培育计划(YBPY2010010)；虹口区医学重点专科建设项目(虹卫2010-91号)

Changes of plasma brain-derived neurotrophic factor in patients with bipolar disorder type Ⅰ

WANG Zuo-wei1,2, LI Ze-zhi1, LIN Zhi-guang1, WU Zhi-guo1, YUAN Cheng-mei1, HONG Wu1, LI Chun-bo1, FANG Yi-ru1   

  1. 1.Shanghai Mental Health Centre, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China；2.Hongkou District Mental Health Center, Shanghai 200083, China
  • Online:2011-11-28 Published:2011-11-29
  • Supported by:

    National Natural Science Foundation of China, 30971047；National High Technology Research and Development Program of China, “863” Program, 2006AA02Z430；Shanghai Jiaotong University School of Medicine Foundation, 2008-6, YBPY2010010；Shanghai Hongkou District Medical Foundation, 2010-91

PDF (PC)

1080

摘要：

目的 探讨血浆脑源性神经营养因子（BDNF）水平与双相障碍Ⅰ型患者躁狂发作的关系。方法 采用全面临床访谈结合美国精神障碍诊断与统计手册第四版（DSM-Ⅳ）轴Ⅰ障碍定式临床检查病人版（SCID-Ⅰ/P）进行评估，入选双相障碍Ⅰ型躁狂发作患者28例（病例组），均给予锂盐联合喹硫平治疗；另选性别构成与年龄匹配的30名健康志愿者作为对照组。双抗体夹心ABC-ELISA法检测对照组和病例组治疗前及治疗后第2、4、8周末的血浆BDNF的质量浓度，分析病例组血浆BDNF水平与Young躁狂量表 (YMRS)评分的相关性。结果 病例组治疗前和治疗后第8周末的血浆BDNF质量浓度显著高于对照组（P<0.05），而治疗后第2、4周末的血浆BDNF质量浓度与对照组比较差异无统计学意义（P>0.05）。病例组治疗前、治疗后第2、8周末的血浆BDNF水平与YMRS评分无相关性（P>0.05），治疗后第4周末血浆BDNF水平与YMRS评分呈显著负相关（r=－0.450, P<0.05）。结论 双相障碍Ⅰ型躁狂发作的疾病状态与血浆BDNF水平的变化缺乏一致性，有待大样本研究进一步验证两者的关系。

关键词: 双相障碍, 躁狂发作, 脑源性神经营养因子, 血浆

Abstract:

Objective To explore the relationship between plasma brain-derived neurotrophic factor (BDNF) and manic episode of bipolar disorder type Ⅰ. Methods With comprehensive clinical review and structured clinical interview for DSM-Ⅳ axis Ⅰ disorders patient version (SCID-Ⅰ/P), 28 patients with manic episode of bipolar disorder type Ⅰ were enrolled (case group), and were treated with lithium and quetiapine. Another 30 gender- and age-matched healthy volunteers were served as controls. Plasma mass concentrations of BDNF in case group and control group were detected by ABC-ELISA before treatment and 2 weeks, 4 weeks and 8 weeks after treatment, and the relationship between plasma mass concentration of BDNF and Young mania rating scale (YMRS) was analysed in case group. Results The plasma mass concentrations of BDNF in case group were significantly higher than those in control group before treatment and 8 weeks after treatment (P<0.05), while there was no significant difference in the plasma mass concentrations of BDNF between two groups 2 weeks and 4 weeks after treatment (P>0.05). In case group, the plasma mass concentrations of BDNF before treatment and 2 weeks and 8 weeks after treatment were not related to the score of YMRS (P>0.05), while the plasma mass concentration of BDNF 4 weeks after treatment was significantly related to the score of YMRS (r=－0.450, P<0.05). Conclusion The episode state of mania in patients with bipolar disorder type Ⅰ is not linearly associated with the plasma level of BDNF, and further studies with large samples are necessary to elucidate the relationship between them.

Key words: bipolar disorder, manic episode, brain-derived neurotrophic factor, plasma